Overview and Specific Aims. The development of research and physician scientists into productive independent translational investigators is one of the most important goals of the principal investigators, the SPORE, the University of Pittsburgh Cancer Institute (UPCI) and the Institution. To accomplish this, the Career Development Program of the University of Pittsburgh Skin Cancer SPORE will pursue the following Specific Aims: 1. To identify and attract research and physician scientists with demonstrated outstanding potential, to develop an independent career in translational research in the area of cutaneous oncology. 2. To provide such research and physician scientists with mentoring, financial support, and a productive stimulating environment, during the formative stages of their careers, to facilitate their development into productive translational investigators. We intend the SPORE Career Development to complement existing award mechanisms designed to address these issues, including recently implemented NIH sponsored debt forgiveness programs. Furthermore, we anticipate that this SPORE Career Development Program will facilitate development of a successful T32 training grant application focused on Cutaneous Oncology. To accomplish these goals, we are not requesting support through the SPORE mechanism, because we would prefer to direct SPORE funds to the translational research projects proposed. Instead, we will utilize $50,000 of committed funds from the UPCI. This resource will be used to fund one Career Development award of $50,000 per year. Awards will be for an initial 1-year period, with the possibility for competitive renewal for a second year. Awardees will be required to devote at least 80% effort overall to translational research. Less than 80% salary support may be requested through this mechanism, enabling trainees to leverage other competitive and institutional sources of research support when appropriate (while maintaining at least 80% effort in translational research)

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA121973-05
Application #
8379337
Study Section
Special Emphasis Panel (ZCA1-RPRB-M)
Project Start
Project End
Budget Start
2012-08-01
Budget End
2013-07-31
Support Year
5
Fiscal Year
2012
Total Cost
$113,424
Indirect Cost
$42,008
Name
University of Pittsburgh
Department
Type
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Mathers, A R; Carey, C D; Killeen, M E et al. (2017) Electrophilic nitro-fatty acids suppress allergic contact dermatitis in mice. Allergy 72:656-664
Davar, Diwakar; Ding, Fei; Saul, Melissa et al. (2017) High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. J Immunother Cancer 5:74
Booth, Laurence; Roberts, Jane L; Sander, Cindy et al. (2017) The HDAC inhibitor AR42 interacts with pazopanib to kill trametinib/dabrafenib-resistant melanoma cells in vitro and in vivo. Oncotarget 8:16367-16386
Najjar, Yana G; Ding, Fei; Lin, Yan et al. (2017) Melanoma antigen-specific effector T cell cytokine secretion patterns in patients treated with ipilimumab. J Transl Med 15:39
Butterfield, Lisa H (2017) The Society for Immunotherapy of Cancer Biomarkers Task Force recommendations review. Semin Cancer Biol :
Lemchak, David; Banerjee, Swati; Digambar, Shaunak S et al. (2017) Therapeutic and prognostic significance of PARP-1 in advanced mycosis fungoides and Sezary syndrome. Exp Dermatol :
Ferris, Laura K; Saul, Melissa I; Lin, Yan et al. (2017) A Large Skin Cancer Screening Quality Initiative: Description and First-Year Outcomes. JAMA Oncol 3:1112-1115
Scharping, Nicole E; Menk, Ashley V; Whetstone, Ryan D et al. (2017) Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol Res 5:9-16
Overacre-Delgoffe, Abigail E; Chikina, Maria; Dadey, Rebekah E et al. (2017) Interferon-? Drives Treg Fragility to Promote Anti-tumor Immunity. Cell 169:1130-1141.e11
Kalinsky, Kevin; Lee, Sandra; Rubin, Krista M et al. (2017) A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). Cancer 123:2688-2697

Showing the most recent 10 out of 191 publications